Legend Biotech names new CEO
Cancer treatment maker Legend Biotech Corp. (LEGN.US) announced its appointment of a new CEO on Tuesday, a month and a half after the sudden departure of its longtime chief executive…
Legend Bio CEO resigns, shares tumble
Drugmaker Legend Biotech Corp. (LEGN.US) said on Monday that Huang Ying resigned as the company’s CEO and member of its board effective July 24, without giving any reason for his departure.…
BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
Drug developer Legend Biotech Corp. (LEGN.US) on Tuesday reported its revenue rose 56% year-on-year to $305.1 million in the first quarter, as it reaped the benefit of strong sales for…
BRIEF: Legend Biotech’s revenue rises 36% in second quarter
Drug maker Legend Biotech Corp. (LEGN.US) on Monday reported strong revenue growth in the second quarter of 2025 as its core cancer drug gained traction. But its net loss also…
NEWS BRIEF: Legend Biotech’s revenue doubles on big gains for CAR-T treatment
Cancer treatment maker Legend Biotech Corp. (LEGN.US) reported on Friday its revenue more than doubled to $187 million in the second quarter from $73 million a year earlier, while its…
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
A potential sale of Legend Biotech may carry a 30% to 50% premium, which could generate up to 55.8 billion yuan for Genscript based on its 48% stake in the…
GenScript losses shrink on strong growth for cancer cell therapy
The pharma company’s losses narrowed 58% last year, as its life sciences and cell therapy businesses experienced strong growth Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year…
Recent Articles
RELATED ARTICLES
-
Legend Bio CEO resigns, shares tumble
- BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
-
iQiyi names Tian Ying as new CFO
IQ.US
- Luzhu Biotech braces for make-or-break launch of shingles shot
- Cancer screening company faces tough IPO test as market cools
-
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
2617.HK
